FDA_Warning_Letters, Import_Alerts_&_EU_Non-Compliances_in_2019
X

Find Drugs for Infections and Infectious Diseases in Preclinical Development in UNITED STATES

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BNT162

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: BioNTech

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration March 17, 2020

            Details:

            Companies will jointly develop BioNTech’s mRNA-based vaccine candidate BNT162 to prevent COVID-19 infection Collaboration aims to accelerate global development of BNT162.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Self-assembling vaccine

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Department of Defense

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement March 23, 2020

            Details:

            Hoth and Voltron, with the support of MGH, will work jointly on exploring and developing this SAV technology as a means to aid patients at risk of being infected with COVID-19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): STI-4398

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 20, 2020

            Details:

            COVIDTRAP is designed to block the SARS-CoV-2 virus from binding and infecting respiratory epithelial cells, which is expected to effectively interrupt the viral life cycle.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Measles vaccine

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Bill & Melinda Gates Foundation

            Deal Size: $5.0 million Upfront Cash: Undisclosed

            Deal Type: Funding March 17, 2020

            Details:

            The new funding will be used for IND-enabling studies and a first-in-human clinical study for measles and rubella vaccination using Vaxxas’ advanced HD-MAP platform.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): COVID-19 drug

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 13, 2020

            Details:

            Beroni Group's development of a medical solution using nanobody technology for the novel coronavirus with Tianjin University in China has advanced into cytological experiments in March 2020.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): INO-4800

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Bill & Melinda Gates Foundation

            Deal Size: $5.0 million Upfront Cash: Undisclosed

            Deal Type: Funding March 12, 2020

            Details:

            Funding will accelerate the testing and scale up of CELLECTRA® 3PSP proprietary smart device for the intradermal delivery of INO-4800, a DNA vaccine for COVID-19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Nitric Oxide

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 12, 2020

            Details:

            Company published evidence suggesting a potential role of inhaled nitric oxide as a supportive measure in treating those patients infected with SARS-CoV-2 and having associated pulmonary difficulties.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): COVID-19 vaccine

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 12, 2020

            Details:

            Greffex said it did not use a living or killed virus for its vaccine and instead used an adenovirus-based vector vaccine, which are genetically engineered.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AT-100

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 11, 2020

            Details:

            Airway is aiming to enter the clinic later this year with AT-100 as an investigational preventive treatment for the serious respiratory disease.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): COVID-19 vaccine

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Emergent BioSolutions

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement March 10, 2020

            Details:

            Emergent will produce the COVID-19 experimental vaccine candidate, based on the proprietary recombinant protein nanoparticle technology platform of Novavax and using their Matrix-M™ adjuvant.

            PharmaCompass